Functional consequences of inhibition of Bruton's tyrosine kinase by ibrutinib in chronic lymphocytic leukemia

Abstract

AbstractThe leukemic B cells from patients with chronic lymphocytic leukemia (CLL) require interactions with non‐malignant cells and matrix in the tissue microenvironment to survive and grow. These interactions are mediated through the B‐cell antigen receptor (BCR), C‐X‐C chemokine receptor type 4 (CXCR4), and a variety of integrins, including VLA‐4. Exciting each receptor type leads to activation of Bruton's tyrosine kinase (BTK), which in turn helps initiate trophic signals that prevent cell death and promote cell activation and growth as well as allowing cells to return to anatomic sites for rescue signals. These represent the two major functional actions targeted by inhibitors of Btk. Here we relate some of the therapeutic actions of ibrutinib, a Btk inhibitor that is extremely helpful for patients with CLL, certain Diffuse Large B‐cell Lymphomas (ABC type), and other non‐Hodgkin's lymphomas, emphasizing that ibrutinib's value results from blocking beneficial signals, not by inducing lethal ones.